Early Onset Immune-Related Adverse Event to Identify Pseudo-Progression in a Patient With Ovarian Cancer Treated With Nivolumab: A Case Report and Review of the Literature

Early Onset Immune-Related Adverse Event to Identify Pseudo-Progression in a Patient With Ovarian Cancer Treated With Nivolumab: A Case Report and Review of the Literature

Background: Immune checkpoint inhibitors (ICIs) have shown clinical benefit in many advanced tumors, however, pseudo-progression is a noted phenomenon of ICIs characterized by radiologic enlargement of the tumor burden, followed by regression. How to differentiate pseudo-progression from progression...

Full description

Bibliographic Details
Main Authors: Hui Li, Xin Zhou, Ding Zhang, Guoqiang Wang, Xiaochun Cheng, Caihong Xu, Bin Yao, Linrong Pang, Jun Chen
Format: Article
Language:English
Published: Frontiers Media S.A. 2020-07-01
Series:Frontiers in Medicine
Subjects:
immunotherapy
ovarian cancer
nivolumab
biomarker
pseudo-progression
Online Access:https://www.frontiersin.org/article/10.3389/fmed.2020.00366/full

Internet

https://www.frontiersin.org/article/10.3389/fmed.2020.00366/full

Similar Items